Title: Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.
Journal: Journal of medicinal chemistry 20110623
1451-82-7
20099-89-2
20099-90-5
2633-50-3
26346-85-0
70-11-1
201404-15-1 | L-Cysteine, N-(acetyl-d3)-S-(phenylmethyl)- (9CI) | AA002DB0 | MFCD12756086
18952-87-9 | 1-Isopropylpyrazole | AA002DOD | MFCD07468920
190064-28-9 | 5-(3,4-Dimethoxyphenyl)cyclohexane-1,3-dione | AA002E81 | MFCD01954969
19070-91-8 | 1-Butanamine, N-butyl-, acetate (1:1) | AA002ENH | MFCD00191381
191-30-0 | Dibenzo[def,p]chrysene | AA002EWS | MFCD00467035
19158-51-1 | Tosyl cyanide | AA002F9P | MFCD00009977
192184-71-7 | 6-Hydroxy-1H-indole-3-carbaldehyde | AA002FMC | MFCD11110391
19258-73-2 | Methyl 2-amino-4,5-dimethylbenzoate | AA002G1M | MFCD11505980
1878-82-6 | (4-Cyanophenoxy)acetic acid | AA002GF0 | MFCD01155938
188121-31-5 | 6-Methyl-5-nitroisoquinoline | AA002GN6 | MFCD11848649